Drugs / Cytovir ADV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01822093 | Dec 2012 → Dec 2016 | disease related to hematopoietic stem cell transplant | Cell Medica Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytovir ADV | “A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed” NCT01822093 ↗ |
| Modality | Cell therapy | “administering adenovirus-specific T-cells (Cytovir ADV)” NCT01822093 ↗ |
| Route | Other | “following infusion of Cytovir ADV” NCT01822093 ↗ |